Medpace (NASDAQ:MEDP) Reaches New 12-Month High - Here's Why

Key Points

• Medpace Holdings, Inc. (NASDAQ:MEDP) reached a new 52-week high of $507.69 during trading, reflecting strong investor interest and activity.
• Brokerage ratings have fluctuated, with UBS lowering Medpace to a "sell" rating while Deutsche Bank raised its target price significantly from $270 to $430.
• In its latest earnings report, Medpace reported $3.10 earnings per share, surpassing estimates and marking a 14.2% increase in revenue year-over-year.

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $507.69 and last traded at $500.76, with a volume of 30159 shares. The stock had previously closed at $500.76.

Analyst Ratings Changes

A number of brokerages have commented on MEDP. UBS Group cut Medpace from a "neutral" rating to a "sell" rating and increased their target price for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft increased their price objective on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. TD Cowen reaffirmed a "sell" rating and set a $366.00 target price (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, Rothschild Redb cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of "Reduce" and a consensus price target of $422.27.

Medpace Trading Up 1.5%

The firm has a market cap of $14.27 billion, a price-to-earnings ratio of 37.78, a P/E/G ratio of 3.13 and a beta of 1.44. The stock's fifty day moving average price is $468.67 and its 200-day moving average price is $362.54.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Transactions at Medpace

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the transaction, the director owned 10,197 shares of the company's stock, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the sale, the vice president owned 57,500 shares of the company's stock, valued at $27,600,000. This trade represents a 14.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 in the last 90 days. Insiders own 20.30% of the company's stock.

Institutional Investors Weigh In On Medpace

Institutional investors have recently modified their holdings of the company. Mawer Investment Management Ltd. purchased a new stake in Medpace during the 1st quarter worth about $212,131,000. Vulcan Value Partners LLC increased its stake in shares of Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock worth $99,159,000 after buying an additional 224,578 shares during the period. Norges Bank acquired a new stake in Medpace in the second quarter valued at approximately $66,597,000. Clarkston Capital Partners LLC purchased a new position in Medpace in the second quarter worth approximately $40,569,000. Finally, Bares Capital Management Inc. grew its holdings in Medpace by 319.2% during the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company's stock worth $49,302,000 after acquiring an additional 119,608 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.